by Elec23 | Oct 22, 2025 | News&events
VisMederi continues to strengthen its engagement in metapneumovirus control and vaccine research, confirming its active role in the international scientific community. At the 10th ESWI Influenza Conference, held in Valencia from 20 to 23 October 2025, Maria Giovanna...
by Elec23 | Aug 5, 2025 | News&events
A new paper from our team is online. The paper dissects the use of pseudotyped viral vectors to study the antibody-mediated immune responses. The pseudotype technology is an important tool for the study of the neutralizing activity in vaccinology and virology, as well...
by Elec23 | May 30, 2025 | News&events
Influenza has been a major global problem for centuries. Although vaccination can reduce the health and economic consequences of an influenza epidemic, current vaccines are far from perfect. Many research teams around the world have worked to create an effective...
by Elec23 | Apr 7, 2025 | News&events
Emanuele Montomoli (CSO & Founder) and Alessandro Manenti (CDO) are co-authors of a new scientific publication on a Phase II/III clinical study evaluating the immunogenicity, safety, and tolerability of a new SARS-CoV-2 booster vaccine. The study represents an...
by Elec23 | Feb 24, 2025 | News&events
VisMederi has expanded its testing portfolio with cutting-edge pseudo-viral platforms, which are critical tools for examining immunogenicity and developing vaccines against emerging infections. These new technologies enable us to test immune responses in a safe and...
